溶血磷脂酸、人附睾蛋白4检测对卵巢癌的早期诊断价值

Objective To explore the specific value of lysophosphatidic acid (LPA) and human epididymis protein 4 ( HE4 ) on the early diagnosis of ovarian cancer. Methods Among the 121female patients serum samples colleted from the local hospital, 31 cases are early ovarian cancer group, 40cases are the nonmalignant ovarian disease group, 50 cases are the healthy check-up female. By means of phosphorus and ELISA,We can analyse the content of LPA and HE4 in serum .Results The value of LPA and HE4 In early-stage ovarian cancer group are( 12.24 ± 6.16) μ mol/L and(102.8 ± 167.3)pmol/L,respectively, much higher than the nonmalignant ovarian disease' s(2.32 ± 1.03) μ mol/L、(34.3 ± 12.1)pmol/L and the health check-up' s(2.04 ± 0.68)μ mol/L、(28.6 ± 8.3)pmol/L, Significant difference (P＜ 0.01). As the early experimental diagnoses for ovarian cancer, the conbination test of LPA and HE4 is better than the any single test of them. The conbination test' s sensitivity is 96.8%, its specificity is 87.8%,its accuracy is 90.1%. Conclusion Detect the LPA and HE4 in the early diagnosis of ovarian cancer has important value for clinical applications, It' s superior than the single use for early diagnosis in ovarian cancer.

The diagnostic value when lysophospholipids acid, epididymis protein 4 used in early ovarian cancer' s detection